Navigation Links
Jennerex Announces Presentations at Upcoming Conferences
Date:12/23/2009

SAN FRANCISCO, Dec. 23 /PRNewswire/ -- Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced that management will present at the following upcoming investor conferences.


    Biotech Showcase 2010
    Tuesday, January 12, 2010
    9:40 a.m. PT
    Marines' Memorial Club and Hotel, San Francisco

    OneMedForum 2010
    Wednesday, January 13, 2010
    2:40 p.m. PT
    Sir Francis Drake Hotel, San Francisco

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .

SOURCE Jennerex Biotherapeutics


'/>"/>
SOURCE Jennerex Biotherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
2. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
3. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
6. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
7. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
8. Macomb County Announces Final 2009 H1N1 Clinic
9. Access MediQuip Announces Release of Partners in Focus Provider Portal
10. Unilens Announces Extraordinary Meeting Results
11. Arrayit Corporation Announces Manufacturing Breakthrough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... WHIPPANY, N.J. , May 18, 2017  Two ... Healthcare Businesswomen,s Association (HBA) during its recent 28 th ... New York City.  The event showcases HBA,s longstanding mission ... the business of healthcare. Cindy Powell-Steffen ... in Bayer,s U.S. Radiology division, and Libby Howe ...
(Date:5/15/2017)...  Amy Baxter MD, chief executive officer and founder ... relief, was awarded a 2017 Top 40 Healthcare Transformer ... at the MM&M Top 40 Healthcare Transformers dinner and ... on May 10, 2017. The dinner followed a full-day ... the pill."  "Innovation goes beyond invention," noted ...
(Date:5/12/2017)... May 12, 2017  The China and Canada ... that consumes less water, energy and detergent, and features a powerful ... LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s panties ... ... is compact, and does not require an external water inlet. ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... On May 24, ... which narrowly passed the U.S. House on May 4, would result in 23 million ... under continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Dr. Alex ... proud to announce a new, informational blog post on insurance options. If a Bay ... insurance plans may help save time and money. Visiting an in-network provider for a ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All ... so many others. “Cactus Jack: Against All Odds” is the creation of published ... D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and ...
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, Inc., a leader ... – a one-day technology conference in San Diego, CA. , At nVerge 2017, ... to fully utilize and enhance their Sage ERP solutions by providing improved visibility and ...
(Date:5/24/2017)... ... 2017 , ... STATEMENT OPPOSING PRESIDENT DONALD TRUMP’S 2018 BUDGET ... budget, “A New Foundation for American Greatness—President's Budget FY 2018,” because it is ... populations, undermines productivity, and destroys the social safety net needed by hardworking but ...
Breaking Medicine News(10 mins):